Mesenchymal Stem Cells (MSC)

Mesenchymal Stem Cells (MSC)

Global Mesenchymal Stem Cells (MSC) Market to Reach US$10.6 Billion by 2030

The global market for Mesenchymal Stem Cells (MSC) estimated at US$4.7 Billion in the year 2023, is expected to reach US$10.6 Billion by 2030, growing at a CAGR of 12.2% over the analysis period 2023-2030. Bone Marrow-sourced MSC, one of the segments analyzed in the report, is expected to record a 13.1% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Adipose Tissues-sourced MSC segment is estimated at 14.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 11.4% CAGR

The Mesenchymal Stem Cells (MSC) market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 11.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.6% and 10.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Mesenchymal Stem Cells (MSC) Market - Key Trends and Drivers Summarized

Mesenchymal stem cells (MSCs), a type of adult stem cell found in various tissues such as bone marrow, adipose tissue, and umbilical cord tissue, hold significant promise for regenerative medicine and therapeutic applications across a spectrum of medical conditions. These cells are prized for their ability to self-renew and differentiate into a variety of cell lineages, including bone, cartilage, muscle, and nerve cells. Their potential is particularly compelling because they can evade immune rejection, a critical factor that enhances their suitability for clinical applications. The ability of MSCs to differentiate is influenced by various factors, including the source of the cells and the conditions under which they are cultured. This process is governed by complex genetic and epigenetic mechanisms that regulate their activation, proliferation, and maturation.

MSCs also exhibit immunomodulatory properties that are crucial for suppressing immune responses and fostering tissue repair, making them valuable in the treatment of autoimmune diseases, spinal cord injuries, and cardiovascular diseases. They promote angiogenesis and tissue regeneration, underscoring their importance in managing diverse medical conditions. MSCs are sourced from a range of tissues, each offering unique advantages and challenges in terms of isolation and expansion. However, their clinical application is hindered by challenges such as cellular heterogeneity, variability, and the need for quality control. To harness the therapeutic potential of MSCs effectively, it is essential to develop standardized methodologies and conduct rigorous safety evaluations.

In the oncological arena, MSCs present a dual role. They have been shown to contribute to tumor growth by promoting angiogenesis, immune evasion, and creating a tumor-supportive microenvironment. Conversely, they exhibit anti-tumor properties, deploying cytokines and other cytotoxic elements to target cancer cells. This dual nature necessitates a nuanced understanding of MSC behavior to optimize their therapeutic use in cancer treatment. Researchers are exploring innovative strategies to leverage MSCs as delivery vehicles for anti-cancer agents, transforming them into `Trojan horses` that can carry therapeutic payloads directly to tumors. The combination of MSCs with biomaterials, which can scaffold the cells and control the release of therapeutic agents, presents a promising avenue to overcome current therapeutic limitations and enhance the efficacy of cancer treatments.

 

 

 

 

 

Select Competitors (Total 56 Featured) -

• Cell Applications Inc.
• Celprogen Inc.
• Cyagen US Inc.
• Genlantis Inc.
• Lonza Group
• Mesoblast Limited
• MilliporeSigma
• Neuromics
• Orthofix International N.V.
• PromoCell GmbH
• R&D Systems Inc.
• ScienCell Research Laboratories
• Stemcell Technologies Inc.
• Stemedica Cell Technologies Inc.
• Thermo Fischer Scientific Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.